108.66 -0.03 (-0.03%)
Pre-market: 6:27AM EST
|Bid||107.51 x 1200|
|Ask||109.88 x 1100|
|Day's range||105.60 - 109.44|
|52-week range||62.55 - 113.41|
|Beta (5Y monthly)||0.81|
|PE ratio (TTM)||39.96|
|Earnings date||29 Apr 2021 - 03 May 2021|
|Forward dividend & yield||5.20 (4.78%)|
|Ex-dividend date||14 Apr 2021|
|1y target est||120.67|
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. In clinical trials, HUMIRA induced clinical remission at Week 8 and maintained remission at Week 52 in patients who responded at Week 8.1,2
From scrolling through social media feeds, to video conferences for work and school, to relaxing with television and video games, Americans are spending approximately 13 hours a day on some type of digital device.1 As the reliance on screens to connect digitally for both professional and personal use continues to rise, more than half of adults suffer from digital eye strain,2 which often includes dry, irritated eyes.
Regeneron Pharmaceuticals (NASDAQ: REGN) and AbbVie (NYSE: ABBV) have managed to deliver strong fourth quarter earnings. Regeneron Pharmaceuticals' fiscal 2020 performance has been quite remarkable, considering the many pressures it faced due to COVID-19 related restrictions. Regeneron's blockbuster retinal disease drug, EYLEA, continues to be a force to reckon with, clocking sales of $7.9 billion globally (in conjucnction with Bayer).